A case of C3 glomerulonephritis successfully treated with eculizumab. 2015

Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
Department of Pediatrics, Division of Nephrology, CHU Sainte Justine and University of Montreal, 3175 Côte Sainte Catherine, H3T1C5, Montreal, QC, Canada.

BACKGROUND C3 glomerulonephritis (C3GN) is a rare form of glomerulopathy that is characterized by predominant C3 deposits. Eculizumab, a humanized monoclonal C5 antibody, has recently emerged as a treatment option for C3GN. We report a C3GN patient successfully treated with eculizumab. METHODS A 5-year-old boy who presented with proteinuria, hematuria, high ASO titers, and low C3 levels was initially diagnosed with post-streptococcal GN. His first kidney biopsy confirmed this diagnosis, but complement investigations identified three alternative pathway dysregulation factors: C3 nephritic factor, complement factor I heterozygous mutation (I398L), and anti-factor H autoantibodies (4,500 AU/ml). A second biopsy performed 11 months after initial presentation (nephrotic range proteinuria) showed a C3GN suggestive of isolated C3 deposits. Despite the use of intensive immunosuppressive therapy (rituximab, corticosteroids, mycophenolate), nephrotic-range proteinuria persisted and a third kidney biopsy showed the same C3GN pattern with more endocapillary proliferation. The serum C5b-9 level was elevated. Eculizumab was initiated and resulted in a significant decline of proteinuria (5.3 to 1.3 g/day) and an improvement in pathologic features. A transient interruption of eculizumab resulted in a rapid rise in proteinuria to 9.3 g/day, which decreased to 0.8 g/day after resumption of treatment. CONCLUSIONS The administration of anti-C5 antibodies may represent a valuable therapeutic option in patients with C3GN.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D008297 Male Males
D008854 Microscopy, Electron Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen. Electron Microscopy
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney

Related Publications

Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
October 2013, Pediatric nephrology (Berlin, Germany),
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
January 2021, Hematology, transfusion and cell therapy,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
January 2018, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
August 2015, Clinical kidney journal,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
April 2019, Critical care explorations,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
January 2020, Clinical nephrology,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
July 2013, Case reports in nephrology and urology,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
January 2012, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
January 2024, Journal of investigative medicine high impact case reports,
Alexis Payette, and Natalie Patey, and Marie-Agnès Dragon-Durey, and Véronique Frémeaux-Bacchi, and Françoise Le Deist, and Anne-Laure Lapeyraque
February 2018, Clinical immunology (Orlando, Fla.),
Copied contents to your clipboard!